Scholars Central

Conference abstract

Highly conserved epitopes of Zika envelope glycoprotein may act as a novel peptide vaccine with high coverage: Immunoinformatics approach

Authors: Marwan Mustafa Badawi Suluiman, Marwa Mohamed Osman, Afra Abd Elhamid Fadl Alla, Ammar Mohammed Ahmedani, Mohamed hamed Abdalla, Mosab Mohamed Gasemelseed, Ahmed Abubakar Elsayed, Mohamed Ahmed Salih

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Zika virus (ZIKV) is positive sense single stranded RNA of Flavivirus genus belonging to the Flaviviridae family. It has neither drug nor protective vaccine and thought to be in relatedness to neurological diseases such as Guillain Barre Syndrome and microcephaly in neonates of infected mothers. The aim of this study is to analyze envelope glycoprotein-E of all Zika strains using in silico approaches looking for conservancy which is further studied to predict all potential epitopes that can be used after in vitro and in vivo confirmation as a therapeutic peptide vaccine. A total of 50 Zika virus variantsâ?? (include 12 from South America) polyproteins retrieved from NCBI database were aligned and the conserved regions of envelope glycoprotein-E were selected for epitopes prediction. We used IEDB analysis resource to predict B and T-cell epitopes and to calculate the population coverage. Epitopes with high scores in both B-cell and T-cell epitopes predicting tools were suggested. Three epitopes were proposed for international therapeutic peptide vaccine for B-cell (AQDKP, TPNSPRAE and TPHWNNK) and two other epitopes designed especially for South America strains (LDKQSDTQYV and EVQYAGTDGPCK). For T-cell epitopes, MMLELDPPF epitope was highly recommended as therapeutic peptide vaccine to interact with MHC class I along with three other epitopes (MAVLGDTAW, KEWFHDIPL and DTAWDFGSV) which showed very good population coverage against the whole world population. Three epitopes showed high affinity to interact with MHC class II alleles (FKSLFGGMS, LITANPVIT and VHTALAGAL) with excellent population coverage throughout the world and South America region. Herd immunity protocols can be achieved in countries with low population coverage percentage to minimize the active transmission of the virus, especially among pregnant women and other groups at risk. We recommend in vitro and in vivo proving the effectiveness of these proposed epitopes as a vaccine as well as to be used as a diagnostic screening test.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Vaccines & Vaccination.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Marwan Mustafa Badawi Suluiman”
  • BylineArticles whose byline prints “Marwa Mohamed Osman”
  • BylineArticles whose byline prints “Afra Abd Elhamid Fadl Alla”
  • BylineArticles whose byline prints “Ammar Mohammed Ahmedani”
  • BylineArticles whose byline prints “Mohamed hamed Abdalla”
  • BylineArticles whose byline prints “Mosab Mohamed Gasemelseed”
  • BylineArticles whose byline prints “Ahmed Abubakar Elsayed”
  • BylineArticles whose byline prints “Mohamed Ahmed Salih”